Table 1.

Patients characteristics.

Characteristics		No DLT (n = 42)	DLT (n = 39)	P value
Gender	Male	29 (69.0%)	31 (79.5%)	.284
	Female	13 (31.0%)	8 (20.5%)
Age	<60	15 (35.7%)	8 (20.5%)	.130
	≥60	27 (64.3%)	31 (79.5%)
Previous radical	Surgery	35 (83.3%)	30 (76.9%)	.822
treatment	Radiotherapy	5 (11.9%)	7 (17.9%)
	SBRT	2 (4.8%)	2 (5.1%)
Initial TNM stage	I	13 (31.0%)	16 (41.0%)	.570
	II	12 (28.6%)	8 (20.5%)
	III	17 (40.5%)	15 (38.5%)
Recurrent interval	<2 yrs	34 (81.0%)	32 (82.1%)	.899
	≥2 yrs	8 (19.0%)	7 (17.9%)
ECOG PS	0−1	41 (97.6%)	36 (92.3%)	.556
	2	1 (2.4%)	3 (7.7%)
Number of lesions	1	28 (66.7%)	33 (84.6%)	.061
	2−3	14 (33.3%)	6 (15.4%)
Smoking history	No	19 (45.2%)	11 (28.2%)	.113
	Yes	23 (54.8%)	28 (71.8%)
Pathology	ADC	28 (66.7%)	15 (38.5%)	.011*
	Others	14 (33.3%)	24 (61.5%)
Specific TKI therapy	No	23 (54.8%)	37 (94.9%)	P < .001*
	Yes	19 (45.2%)	2 (5.1%)

ADC = adenocarcinoma, ALK = anaplastic lymphoma kinase, DLT = definitive local therapy, ECOG PS = Eastern Cooperative Oncology Group Performance status, EGFR = epidermal growth factor receptor, SBRT = stereotactic body radiotherapy, TKI = tyrosine kinase inhibitor.

^*P < .05.